

Company Provoxis plc
Headline Re Agreement
Released 07:00 16-Nov-07

PROVEXIS plc
(“Provoxis” or the “Company”)

**EXCLUSIVE FRUITFLOW[®] TECHNOLOGY ASSESSMENT AGREEMENT WITH THE
COCA-COLA COMPANY**

Provoxis plc (PXS.L), which discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, announces the signing of a 12 month exclusive technology assessment agreement for its patented Fruitflow[®] anti-thrombotic technology with The Coca-Cola Company.

The exclusivity agreement covers all beverages, with the exception of mini-drinks. During the assessment period both parties will carry out a programme of work including consumer testing, commercial assessment and finalising regulatory approval in a range of territories. Subject to positive results in these areas, the parties intend to proceed to a licensing agreement during the period of exclusivity.

There are four sectors in which Provoxis is seeking major partnerships, namely, food and dairy, beverages, products for deep vein thrombosis, and dietary supplements and medical products. The Company has an existing collaboration agreement with Unilever for certain formats within the food and dairy sectors.

-ends-

For further information please contact:

Stephen Moon, Chief Executive
Provoxis plc

Tel: 01753 752290

Tom Griffiths/Alasdair Younie
Arbuthnot Securities

Tel: 020 7012 2000

Chris Steele
Adventis Financial PR

Tel: 020 7034 4759